McKesson (MCK)
(Delayed Data from NYSE)
$556.15 USD
-0.55 (-0.10%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $556.37 +0.22 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$556.15 USD
-0.55 (-0.10%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $556.37 +0.22 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
The Zacks Analyst Blog Highlights McKesson, Corteva, Atmos Energy and National Fuel Gas
by Zacks Equity Research
McKesson, Corteva, Atmos Energy and National Fuel Gas are part of the Zacks top Analyst Blog.
3 Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why Investors Should Hold Myriad Genetics (MYGN) Now
by Zacks Equity Research
Myriad Genetics' (MYGN) expansion across the globe, banking on myChoiceCDx test sales, seems impressive.
ResMed (RMD) Gains on Product Uptake Even as Expenses Rise
by Zacks Equity Research
The continued uptake of ResMed's (RMD) core non-invasive ventilation and life support ventilation solutions for COPD and neuromuscular disease is encouraging.
Here's Why You Should Hold on to OPKO Health (OPK) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.
4 Top-Ranked Defensive Stocks to Buy Amid Market Swings
by Snehadri Nag
Here we mention four defensive stocks, namely Corteva (CTVA), Atmos Energy, National Fuel Gas Company and McKesson with strong prospects to beat the market whims.
McKesson (MCK) Stock Moves -1.06%: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed at $343.27 in the latest trading session, marking a -1.06% move from the prior day.
3 Medical Stocks Displaying Remarkable Relative Strength in 2022
by Derek Lewis
In addition to favorable price action, all three carry a strong growth profile, making them appear even more enticing.
Stryker's (SYK) OptaBlate Tumor Ablation System Gets FDA Nod
by Zacks Equity Research
Stryker's (SYK) OptaBlate bone tumor ablation system is set to offer a reliable solution for people living with painful metastatic tumors.
Bruker (BRKR) Gains From New Product Bookings Amid Competition
by Zacks Equity Research
Bruker's (BRKR) revenue recognition from one gigahertz class NMR system and continued uptake of the timsTOF platform hold promise.
Walgreens Boots' (WBA) Product Expansion Aids Amid Rivalry
by Zacks Equity Research
Sales contributions from Walgreens Boots' (WBA) newly-formed Walgreens Health segment instill investors' optimism.
Here's Why Investors Should Retain Amedisys (AMED) Stock for Now
by Zacks Equity Research
Investors are optimistic about Amedisys' (AMED) better-than-expected earnings and notable buyouts.
PerkinElmer's (PKI) Reagent Kit Receives FDA Clearance
by Zacks Equity Research
PerkinElmer's (PKI) T-Cell Select reagent kit is expected to allow for a more automated workflow following the FDA's approval.
Is First Trust Consumer Staples AlphaDEX ETF (FXG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXG
The Zacks Analyst Blog Highlights NextEra Energy, Southern Company, PepsiCo, Corteva and McKesson
by Zacks Equity Research
NextEra Energy, Southern Company, PepsiCo, Corteva and McKesson are included in this Analyst Blog.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN's (QGEN) better-than-expected results and solid genomics uptake.
Abbott (ABT) Reports Favorable Findings From RELIEF Study
by Zacks Equity Research
The latest data from the RELIEF Study suggests a lower rate of hospitalizations from serious diabetes-related events with Abbott's (ABT) FreeStyle Libre system.
3 Reasons to Retain NextGen (NXGN) Stock in Your Portfolio
by Zacks Equity Research
NextGen's (NXGN) strong product portfolio and solid prospects in the RCM space raise optimism about the stock.
Here's Why You Should Bet on ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies.
Here's Why You Should Buy McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Medtronic (MDT) Gets FDA's 510(k) Nod for Pediatric ICM
by Zacks Equity Research
This latest approval broadens Medtronic's scope within its Cardiovascular Diagnostics and Services wing within broader Cardiovascular business.
Bet on These 5 Ultra-Defensive Stocks for the Rest of 2022
by Nalak Das
We have narrowed our search to five low-beta high-yielding defensive stocks that have strong potential for the rest of 2022. These are: NEE, SO, PEP, CTVA and MCK.
Charles River (CRL) Gains From Growing Demand Amid Macro Woes
by Zacks Equity Research
Charles River (CRL) continues to expect that the growth rate will approach 20% in the second half of 2022.
McKesson (MCK) Stock Pares Gains Following Rx Savings Buyout
by Zacks Equity Research
McKesson (MCK) agrees to buy privately-held Rx Savings Solutions in alignment with its strategic plan of creating accessible and affordable treatment options.